Showing posts with label CORONAVIRUS MUTATION. Show all posts
Showing posts with label CORONAVIRUS MUTATION. Show all posts

Tuesday, June 30, 2020

POLITICO NIGHTLY: Covid swamps Trump Country







Jun 29, 2020

POLITICO Nightly: Coronavirus Special Edition
Presented by
With help from Myah Ward
Graphic showing new cases of Covid-19 divided by states that voted for Trump in 2016 and states that voted for Clinton in 2016
THE TRUMP BUMP On the pandemic’s first peak in early April, the states that voted for Democratic candidate Hillary Clinton accounted for 67 percent of new Covid-19 cases. For the newest peak, which we’re still climbing, the states that voted for President Donald Trump have an even larger share: They accounted for 73 percent of new cases on June 28.
Welcome to POLITICO Nightly: Coronavirus Special Edition. Renu is off today, and Nightly will also be off July 3-6. It will return Tuesday, July 7. Reach out with tips: rrayasam@politico.com or on Twitter at @renurayasam.

A message from the American Cancer Society Cancer Action Network:
Congress addressed the affordability of Covid-19 testing and treatment. Cancer care needs the same. It’s time to reduce out-of-pocket costs and ensure cost-sharing assistance benefits cancer patients. Congress: cancer patients need you to act quickly to remove hurdles to quality care.

THE GLOBAL FIGHT
RYAN HEATH’S EUROPEAN ‘VACATION’  Can you still travel to Europe from the United States? In theory it’s banned, but if you’re willing to read the fine print, the answer could be yes.
I’m an Australian by birth, and lived in Brussels until 2019. After eight years of waiting, I was granted Belgian citizenship last month. My problem: no documents to prove it, and a European Union ban on foreign visitors. And even if I somehow managed to get in, I might not get out: Belgium banned its citizens from leaving, to get the virus further under control. But Belgium relaxed that restriction this month, so I decided to seize my chance to get my citizenship documents before the doors slammed shut again.
That required four international flights in a 48-hour dash to Europe last week. My advantage over the tens of thousands who made similar dashes home in March after Trump’s ban on European travel to the U.S.: Most people have been scared off flights now.
First lesson: There’s no common understanding of what it takes to control Covid-19, and we’re all absorbed in our internal national debates instead of creating common global practices. The most obvious point of difference: masks.
To enter Europe, I flew direct from New York’s John F. Kennedy airport to Amsterdam. (My booking said Delta, but the plane and staff were from KLM, the Dutch airline.) After self-declaring that I was Covid-free, I wrapped my face in a bandana, took a plastic bag of cookies and Coca-Cola from the flight attendant and knocked myself out with a sleeping pill. Having a row of three seats to myself in coach helped.
Most of the flight passed without incident, until a man several rows away removed his mask, prompting the man in the seat behind to snap at him, leading to an argument the flight attendant had to break up.
Amsterdam’s Schiphol airport was a different mask situation. Like JFK it was a near ghost town, but unlike JFK the staff were mostly mask-free.
In New York City, I’ve grown used to wearing my mask whenever I leave my apartment. Even Senate Majority Leader Mitch McConnell and Vice President Mike Pence — bucking Trump — have emphasized there is no stigma associated with masks.
In Europe, the attitude seems to be a kind of Covid autopilot. As if to say: We already did the hard work of national lockdowns, so now we’ll coast through a mask-free summer.
The only masked airport staffer I saw in Amsterdam didn’t see the irony of pulling down her mask to yell at passengers standing too close to each other — making herself the most likely super-spreader in line.
Dutch border guards waved me into Europe, no questions asked. For my flight to Brussels, we took a bus from the flight gate to the plane. The driver taped-off a three-yard space around his seat for protection, but his concern didn’t extend to his passengers. We were crammed in the bus while he drove in luxurious isolation. The most shameful part: We all accepted the double standard in silence.
In Belgium — the country with the highest declared per capita Covid-19 death rate in the world: 840 deaths per million, more than double the U.S. with 389 deaths per million — I walked through a temperature scanner but faced no other airport checks for Covid.
Still scarred by the relentless U.S. infection numbers I started by keeping my mask on. But as the Belgians laughed their way through brunch and stared at me as I paid for my meal in my mask, that mask started to slip. Dinner took place mask-free in between discrete plastic screens erected between the booths at a local brasserie.
Covid-19 helped me in my mission to get a Belgian identity card: The country’s famous red tape is now slashed, allowing me to fly out within 24 hours of requesting my ID.
The trip home took 23 hours instead of the usual eight, including a stopover in Copenhagen, Denmark. The airline insisted we could have only one piece of carry-on luggage on the nearly empty plane “for Covid reasons.” Yet aside from one business class passenger everyone else was crammed into six rows in the middle of the plane.
In Copenhagen, armed with a three-line letter from a news source saying we were meeting for coffee, I skirted a Danish ban on most European and all U.S. visitors. I didn’t see a mask outside of the airport.
I am married to an American, but I expected a grilling upon check-in for my flight back to the U.S., so I brought not just my passport but my marriage certificate. Neither seemed to impress the U.S. Customs and Border Protection officers at Newark International, who whisked me into an interview room. The agent checking my file studied opinion polling in college and after 20 minutes of pleasant election chat, he agreed I was a political journalist married to an American, and therefore an exception to Trump’s European travel ban.
I agreed to self-quarantine for 14 days and made it out of the baggage area just in time for yet another work Zoom call.
German Chancellor Angela Merkel and French President Emmanuel Macron meet in the grounds of Schloss Meseberg in Gransee, Germany.
German Chancellor Angela Merkel and French President Emmanuel Macron meet on the grounds of Schloss Meseberg in Gransee, Germany. | Getty Images
PALACE INTRIGUE
PENCE’S WEEKEND SHIFTS  A televised coronavirus task force briefing on Friday, organized at the vice president’s direction on a day’s notice, revealed an undercurrent of fear behind the scenes of the federal government. Over the weekend, Pence stepped up his urgency. The striking shift in the vice president’s tone — from zealously defending Trump’s push to reopen the U.S. economy to complimenting governors today for halting their states’ reopenings — underscores his thorny position as he works to balance his and Trump’s political futures. Inside the Department of Health and Human Services, Gabby OrrAdam CancrynNancy Cook and Dan Diamond write, officials have agonized over Pence’s recent messages on coronavirus, saying that his ever-sunny tone could confuse Americans about the actual risks of the outbreak.

TOMORROW AT 1 p.m. EDT - A POLITICO TOWN HALL: AMERICA AT A TIPPING POINT: The killing of George Floyd sparked demonstrations against police brutality and racial injustice around the world. One month later, join POLITICO Live for a town hall to reflect on the past and reckon with what is next to come. Featured guests include Julián Castro, former secretary of HUD and Democratic presidential candidate; Vanita Gupta, president and chief executive of the Leadership Conference on Civil and Human Rights; Rashad Robinson, civil rights leader and president of Color of Change; and Rep. Karen Bass (D-Calif.), chair of the Congressional Black Caucus. Additional guests TBA. REGISTER HERE.


FIRST IN NIGHTLY
RIPPLE EFFECTS Top Trump administration officials say drug overdose deaths are surging , driven by increased substance use due to anxiety, social isolation and depression. A White House drug policy office analysis shows an 11.4 percent year-over-year increase in overdose fatalities for the first four months of 2020, confirming experts’ early fears that precautions like quarantines and lockdowns combined with economic uncertainty would exacerbate the addiction crisis, health care reporter Brianna Ehley writes.
“The pandemic has caused my level of concern to go up,” White House Drug Czar Jim Carroll told POLITICO in an interview, acknowledging overdose deaths were already starting to rise in the past year after posting the first decline in three decades, in 2018. The surge is prompting the drug policy office and federal agencies to convene regular meetings to size up how the pandemic has disrupted the opioid response.
The pandemic put on hold a billion-dollar research program focused on new forms of addiction treatment, as part of a broader freeze on non-Covid work at the National Institutes of Health.
TALKING TO THE EXPERTS
Nightly’s Myah Ward talked about the mutating coronavirus with Mark R. Schleiss, a professor of pediatrics at The University of Minnesota Medical School and an investigator at the university’s Institute for Molecular Virology. This conversation has been edited.
Is coronavirus mutating?
Yes. But I think the real question is, is it mutating in any way that’s surprising or unusual for an RNA virus? And the answer to that is no, it's not. Part of being a good, card-carrying member of the RNA virus club is that you mutate.
The mutations are actually incredibly useful for us in understanding how this virus has circulated around the globe. Most of the viral infections that swept across the eastern seaboard — New York, Boston, Washington — earlier this spring, those are direct introductions of the infection from Europe. And we know that because the virus mutates, and so we can track those mutations and study how the virus disseminates around the world.
How does mutation affect vaccine development?
Every big pharma group has a vaccine that’s in various stages of preclinical development or clinical trials. Almost all of those are templated on the original sequence from the West Coast, from China.
We have an urgent need to have a vaccine immediately. But we also need to start planning about what a strategy is going to be for immunizing against this over the next 20 years. I think that vaccination is ultimately going to be like the flu shot. It’s going to be probably annual, and it’s probably going to be adjusted and tweaked over time.
What about the chatter that suggests a strain in Europe might be worse than the one in China, for example? Or that there’s a different virus on the West Coast than the East Coast? Is there any truth to that?
It’s definitely true that the origins of the virus in China spread in both directions around the globe, and what we encountered on the West Coast had some genetic differences from what we encountered on the East Coast.
Can people be reinfected with different strains of the virus?
I think it’s happening. There are two issues. One is, are you getting reinfected with a new strain that’s really different from the first strain you got? But the second thing is that even if the virus didn't change at all — which would be impossible — there’s still a lot of uncertainty about the duration of immunity. So do you keep an antibody on board for the rest of your life? Do you lose it over time? There are lots of papers coming out that people who have been infected and been sick, don't make a very good antibody response and it's not very long lasting. Those papers to me are a little surprising because they fly in the face of what we believe to be true for most viral infections.
Would these mutations change anything about how the virus might attack someone, or what symptoms they might have?
There's no convincing molecular data that says that the viruses are more or less pathogenic.
The only mutation that seems to have been associated with increased pathogenicity — that is to say, increased ability to make you sick — is a mutation that is being called in the scientific community and medical community the D614G mutation.
Are we seeing that strain of the virus everywhere, or is it concentrated in certain regions?
It’s being seen really all over the world now. I think that for every D614G, there are 10,000 other variants out there. Nobody notices them because they don’t seem to change the ability of the virus to cause disease. It’s a bad disease anyway even without that mutation.
A broader, more important point is not to worry about necessarily this specific mutation because even viruses without the mutation can kill you. And we need to practice social distancing and public health measures until we can figure out how to get this all under control.

A message from the American Cancer Society Cancer Action Network:
Advertisement Image 

ASK THE AUDIENCE
Nightly asks you: How has the pandemic changed your July 4 holiday? Send us your answer using our form, and we’ll include some of them in our Thursday edition.
AROUND THE NATION
STATES STEP BACK  The reopenings state and local leaders hoped would make summer slightly more normal have been paused or, in particular hot spots, rolled back. A brief snapshot of the areas nationwide hitting the brakes:
No indoor dining in New Jersey: Democratic Gov. Phil Murphy said he will not allow restaurants to reopen for indoor dining this week as originally planned, following spikes of coronavirus cases in other states that have reopened on a more aggressive timeline, Katherine Landergan writes. “We must hit pause on the resumption of indoor dining, which was to resume this Thursday,” Murphy said during his daily briefing in Trenton. “Given the current situation in numerous other states, we do not believe it is prudent at this time to push forward, in effect, with what is a sedentary indoor activity.”
NYC may follow suit: New York Playbook co-author Erin Durkin writes the city may delay allowing indoor dining amid signs it poses a risk of spreading the coronavirus, Democratic Mayor Bill de Blasio and Gov. Andrew Cuomo said today. The city is set to enter the third phase next Monday of its reopening, which was scheduled to include indoor dining. But both New York leaders say they are seriously considering nixing the reopening of indoor restaurants and bars.
Jacksonville masks up: Jacksonville, where the Republican National Convention is slated to be held in August, instituted a city-wide mask order today to stem the spread of coronavirus. The order requires indoor-mask wearing only — not an outside mandate that other local governments in Florida have passed. As the number of cases in the city and state rise, Jacksonville’s Republican Mayor Lenny Curry, his staff and health care experts have been discussing a mask order for more than a week, two sources said. A final turning point for Curry came after the decisions by the Coast Guard and Navy, which has two facilities in Jacksonville, ordering indoor mask-wearing.
ON OUR RADAR
WHITE HOUSE: TRUMP STILL NOT BRIEFED Trump’s top spokesperson said the president still has not received an intelligence briefing on reports that a Russian intelligence unit offered bounties to the Taliban to kill coalition soldiers in Afghanistan, and she also contradicted the president’s assertion that such intelligence had been deemed not credible, Caitlin Oprysko writes.
“There is no consensus within the intelligence community on these allegations,” White House press secretary Kayleigh McEnany told reporters today during a news briefing when explaining why Trump had not been briefed yet, disputing reports from multiple news outlets that the intelligence had been included in Trump’s daily briefing. In fact, McEnany asserted, there are “dissenting opinions” from some in the intelligence community about the allegations, first reported by The New York Times over the weekend, though she said their veracity is still being evaluated. She did not specify who within the intelligence community has disputed the intelligence.
Nightly video player of White House press secretary Kayleigh McEnany
COVID-2020
ALTAR EGO A month ago, Trump pushed governors to let churches reopen. Now several coronavirus clusters are tied to houses of worship across the country. White House reporter Gabby Orr explains in the latest POLITICO Dispatch why churches can be super-spreaders — and why Trump is in a bind as he tries to keep evangelical voters on his side.
Play audio

LISTEN IN FOR CRITICAL NEWS AND NEEDED CONTEXT IN 15 MINUTES OR LESS: The nation is moving through the phases to reopen as Sunbelt states face a spike in coronavirus cases. Americans are demanding action to address racial injustice and police reform. Tens of millions remain out of work, and election season is upon us. Struggling to keep up with the never-ending news cycle? Keep up to speed with the essential news of the day with POLITICO Dispatch, a short, daily podcast that cuts through the news clutter. Subscribe today.


NIGHTLY NUMBER
200,000
The number of adults who would become eligible for Medicaid in Oklahoma if voters approve a ballot measure Tuesday . Oklahoma would become the first state to broadly expand government-backed health insurance to many of its poorest residents since the beginning of a pandemic that has stripped many people of coverage.
PARTING WORDS
LA’S STRUGGLES NOT CONFIDENTIAL — Los Angeles County’s cases surged past 100,000 today, with 2,903 new cases — the largest single-day number of new infections. Democratic California Gov. Gavin Newsom has mandated the closing of bars, wineries, tasting rooms and breweries in Los Angeles and six other counties. Could restaurants be next?
Half of inspected restaurants and bars in LA are failing to comply with Covid-19 protocols, Eater Los Angeles reports.

A message from the American Cancer Society Cancer Action Network:
COVID-19 has shone a spotlight on the significant barriers to affordable health care that cancer patients have long faced. Policymakers took action to address the affordability of COVID-19 testing and treatment. Congress must do the same for cancer patients by removing the red tape of prior authorization and step therapy, reducing out-of-pocket costs, and ensuring cost-sharing assistance directly benefits patients. Learn more.

Did someone forward this email to you? Sign up here.

Follow us on Twitter
Renuka Rayasam @renurayasam

FOLLOW US

 POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA










Wednesday, June 17, 2020

COVID-19, AN RNA VIRUS, WHAT WE KNOW & DON'T KNOW and MUTATIONS



I compiled a list of some significant 'what we know about COVID-19' 
articles for myself. 

COVID-19 is an RNA VIRUS - that means it mutates, just like the common cold 
or flu.

RNA means it only has a single strand that prevents 'proof reading' when it 
reproduces. Reproduction is sloppy. 

Those mutations raise serious questions about a VACCINE,  just as we have no 
vaccine for the common cold and no single vaccine for the flu.

A mutation on the outer shell of COVID-19 might render a vaccine useless. 
Frankly, we don't know.


The ONLY EFFECTIVE treatment is PREVENTION - face masks, social distancing 
and STAY AT HOME. 




FROM POLITICO NIGHTLY: 
STRONG MEDICINE  For weeks doctors and nurses around the country had no real handbook for how to treat the Covid patients that started showing up in their emergency rooms. They had some insight from clinicians in Italy and China and experience treating patients with respiratory ailments, but early treatments included a lot of frantic guesswork.
Now, five months after the first Covid patient walked into a clinic in Everett, Wash., there’s still no FDA-approved therapy or treatment for the virus. In fact, there are two fewer drugs with even a preliminary nod from the agency: The FDA pulled its emergency use authorizations today of chloroquine and hydroxychloroquine, the antimalarial drug touted by President Donald Trump as a Covid treatment.
There are still far more questions than answers when it comes to managing Covid patients. But doctors have made some progress. About 560,000 Covid patients are known to have recovered, according to Johns Hopkins University, though the figure is almost certainly higher because not all states track recoveries and not every infected person goes to the hospital. Here’s a look at what we’ve learned about treating Covid, and what doctors have yet to figure out.
What we got wrong — In the early days of the pandemic, doctors were more willing to try off-label drugs without the usual vetting process, said Daniel Culver, a pulmonary and critical care physician at the Cleveland Clinic who leads a committee that evaluates Covid clinical trial research. That’s partly behind the rise and now fall of hydroxychloroquine. Clinical trials are still ongoing, but the drug’s effectiveness at treating Covid remains questionable.
What we are learning — Evidence is mounting that the antiviral drug remdesivir is effective at helping severely infected Covid patients with low oxygen levels. It’s now the only drug with emergency use authorization from the FDA.
There are hundreds of trials underway for dozens of Covid treatments. Some therapies, like using convalescent plasma from recovered patients to treat the critically ill, are being studied but so far there’s no definitive evidence on whether they are effective.
What we learned not to do — Doctors now believe it’s no longer a good idea to intubate — meaning put on a ventilator — all patients with low oxygen, said Amy Compton-Phillips, chief clinical officer for Providence Health System, which has 51 hospitals including the one that treated the first U.S. Covid patient.
Early on, Compton-Phillips said, her system relied on the advice of doctors in Italy and China to quickly put patients on a ventilator because it was thought to better protect health care workers and because the disease progressed so rapidly. But over time, the health system, which created a registry to track care for Covid patients across its hospitals, realized many patients didn’t need the invasive procedure, which comes with its own risks, right away. Instead the hospital tried other procedures to help patients boost oxygen levels, like proning patients — putting them on their stomachs — to help them inflate their lungs. Over the time, the health system cut its intubations in half, and mortality rates also declined.
What we know now about treating complications — Doctors also began to realize that Covid was more than just a respiratory disease — it can affect all organs and in particular kidneys. Up to 15 percent of patients hospitalized with Covid develop acute kidney injury and many need dialysis.
Intensive-care doctors now pay more attention to how much fluid they are giving patients, being more careful not to flood their lungs and other organs. And they focus more on keeping Covid patients from developing blood clots, which have led to amputations, strokes and other complications.
And hospitals are working on preventing infections by reducing the use of invasive procedures like catheters and better isolating infected patients. “It’s a question of being systematic and careful rather than a eureka thing,” Culver said. “Everyone wants to focus on bells and whistles, but the blocking and tackling part is the most important.”
What we still don’t know  “We’re not even at the end of the beginning for learning about this virus,” Compton-Phillips said. Researchers are trying to figure out answers to the biggest questions including how to intervene early to keep the virus from becoming severe, what are the long-term complications of a Covid infection and why it has been more lethal in black and Hispanic populations.







New coronavirus mutation might make it even more infectious





COVID-19: How many strains of the new coronavirus are there?


SARS-CoV-2 is an enveloped RNA virus, which means that its genetic material is encoded in single-stranded RNA. Inside a host cell, it makes its own replication machinery.
RNA viruses have exceptionally high mutations rates because their replications enzymes are prone to errors when making new virus copies.




Virologist Prof. Jonathan Stoye, a senior group leader at the Francis Crick Institute in London in the United Kingdom, told Medical News Today what makes virus mutations significant.
“A mutation is a change in a genetic sequence,” he said. “The fact of a mutational change is not of primary importance, but the functional consequences are.”
If a particular genetic alteration changes the target of a drug or antibody that acts against the virus, those viral particles with the mutation will outgrow the ones that do not have it.
“A change in a protein to allow virus entry into a cell that carries very low amounts of receptor protein could also provide a growth advantage for the virus,” Prof. Stoye added.
“However, it should be stressed that only a fraction [of] all mutations will be advantageous; most will be neutral or harmful to the virus and will not persist.”
“Mutations in viruses clearly do matter, as evidenced by the need to prepare new vaccines against [the] influenza virus every year for the effective prevention of seasonal flu and the need to treat HIV-1 simultaneously with several drugs to [prevent the] emergence of resistant virus.”

– Prof. Jonathan Stoye
The team studied five nasal swab samples that had a positive SARS-CoV-2 test result. They found that one of these had a deletion, which means that a part of the viral genome was missing. To be precise, 81 nucleotides in the viral genetic code were gone.
Previous research indicated that similar mutations lowered the ability of the SARS virus to replicate.
Another study, this time in the Journal of Translational Medicine, proposed that SARS-CoV-2 had picked up specific mutation patterns in distinct geographical regions.
The researchers, from the University of Maryland in Baltimore and Italian biotech company Ulisse Biomed in Trieste, analyzed eight recurrent mutations in 220 COVID-19 patient samples.
They found three of these exclusively in European samples and another three exclusively in samples from North America.
Another study, which has not yet been through the peer review process, suggests that SARS-CoV-2 mutations have made the virus more transmissible in some cases.
In the paper, Bette Korber — from the Los Alamos National Laboratory in New Mexico — and collaborators describe 13 mutations in the region of the viral genome that encodes the spike protein.
This protein is crucial for infection, as it helps the virus bind to the host cell.
The researchers note that one particular mutation, which changes an amino acid in the spike protein, “may have originated either in China or Europe, but [began] to spread rapidly first in Europe, and then in other parts of the world, and which is now the dominant pandemic form in many countries.”
Prof. Stoye commented that the results of this study are, in some ways, not surprising.
“Viruses are typically finely tuned to their host species. If they jump species, e.g., from bat to human, a degree of retuning is inevitable both to avoid natural host defenses and for optimum interaction with the cells of the new host,” he said.
“Random mutations will occur, and the most fit viruses will come to predominate,” he added. “Therefore, it does not seem surprising that SARS-CoV-2 is evolving following its jump to, and spread through, the human population. Clearly, such changes are currently taking place, as evidenced by the apparent spread of the [mutation] observed by Korber [and colleagues].”
However, Prof. Stoye does not think that it is clear at this point how mutations will drive the behavior of SARS-CoV-2 in the long term.
“Fears about SARS-CoV-2 evolution to resist still-to-be-developed vaccines and drugs are not unreasonable,” he explained. “Nevertheless, it is also possible that we will see evolution to a less harmful version of the virus, as may well have occurred following initial human colonization by the so-called seasonal coronaviruses.”

Opinions remain divided 

Earlier this year, researchers from Peking University in Beijing, China, published a paper in National Science Review describing two distinct lineages of SARS-CoV-2, which they termed “S” and “L.”
They analyzed 103 virus sequence samples and wrote that around 70% were of the L lineage.
However, a team at the Center for Virus Research at the University of Glasgow in the U.K. disagreed with the findings and published their critique of the data in the journal Virus Evolution.
“Given the repercussions of these claims and the intense media coverage of these types of articles, we have examined in detail the data presented […] and show that the major conclusions of that paper cannot be substantiated,” the authors write.
Prof. David Robertson, head of Viral Genomics and Bioinformatics at the Centre for Virus Research, was part of the team. MNT asked his views on the possibility of there being more than one strain of SARS-CoV-2.
“Until there is some evidence of a change in virus biology, we cannot say that there are new strains of the virus. It’s important to appreciate that mutations are a normal byproduct of virus replication and that most mutations we observe won’t have any impact on virus biology or function,” he said.
“Some of the reports of, for example, amino acid changes in the spike protein are interesting, but at the moment, these are at best a hypothesis. Their potential impact is currently being tested in a number of labs.”
Prof. Stoye thinks that it is “more a case of semantics rather than anything else” at the moment.
“If we have different sequences, we have different strains. Only when we have a greater understanding of the functional consequences of the evolutionary changes observed does it make sense to reclassify the different isolates,” he said.
“At that point, we can seek to correlate sequence variation with prognostic or therapeutic implications. This may take a number of years.”

Serotypes and future research

So, what kind of evidence are skeptical scientists looking for in the debate around multiple SARS-CoV-2 strains?
MNT asked Prof. Martin Hibberd, from the London School of Hygiene and Tropical Medicine in the U.K., to weigh in on the debate.
“For virologists, ‘strain’ is rather a subjective word that does not always have a clear specific meaning,” he commented.
“More useful in the SARS-CoV-2 situation would be the idea of ‘serotype,’ which is used to describe strains that can be distinguished by the human immune response — an immune response to one serotype will not usually protect against a different serotype. For SARS-CoV-2, there is no conclusive evidence that this has happened yet.”
“To show that the virus has genetically changed sufficiently to create a different immune response, we would need to characterize the immune protection and show that it worked for one serotype and not for another,” he continued.
Prof. Hibberd, who has been researching SARS-CoV-2 mutations, explained that scientists are studying neutralizing antibodies to help them define a serotype for SARS-CoV-2. These antibodies can prevent the virus from infecting a host cell, but they may not be effective against a new strain.
“Several groups around the world have identified a specific mutation in the SARS-CoV-2 spike protein, and they are concerned that this mutation might alter this type of binding, but we cannot be sure it does that at the moment. More likely, this mutation will likely affect the virus binding to its receptor […], which might affect transmissibility.”
– Prof. Martin Hibberd
“We ideally need experimental evidence, [such as a] demonstration of a mutation leading to a functional change in the virus in the first instance, and secondly a demonstration that this change will have an impact in [people with the infection],” Prof. Robertson suggested.
He pointed to lessons that experts learned during the 2014–2018 Ebola outbreak in West Africa, where several research groups had suggested that a mutation had resulted in the virus becoming more easily passed between people and more deadly.
Cell culture experiments showed that the mutated virus was able to replicate more rapidly. However, when scientists subsequently studied this in animal models, they found that it did not behave any differently than stains without the mutation.
Scientists around the world continue to search for answers to the many outstanding questions around SARS-CoV-2. No doubt, we will see more research emerge in the coming months and years that will assess the impact of SARS-CoV-2 mutations on the COVID-19 pandemic and the future of this new coronavirus.
For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here



This tracks the spread:

The world struggled to understand how COVID-19 spread during the pandemic’s first four months, but genetic sequences of the coronavirus reported by laboratories tell the real story—when the virus arrived in each place and where it came from. The sequences, which advance from left to right in the graphic, show that the virus jumped from an animal to humans in China, humans transmitted it to one another within China, then people traveling from there spread it globally person to person. The virus had not mutated significantly as of March 31, 2020; human contact created the pandemic, not a wildly evolving pathogen. Mapping the spread also substantiates actions that could have best mitigated it: faster, wider testing in China; earlier, stricter global travel bans and isolation of infected people; and more immediate social distancing worldwide.





The WORLD HEALTH ORGANIZATION was the sole source of scientific information from which Daffy Don pulled US FUNDING. 

Since this is a global pandemic, the US should be leading in global efforts to research and find solutions. 

We've short-changed ourselves in this effort. 


The US should be leading the World in SCIENCE and RESEARCH. 
We're not. How pathetic!











Trump's Friday Meltdown: Begging Iran, Ditching Ukraine, and Blaming Everybody But Himself – 7/31/26

                                               LOTS OF POSTS IGNORED BY BLOGGER..... OR REMOVED ON THEIR WHIM! ALL POSTS ARE AVAILABLE ON MI...